Variant ofDiscover the Coronavirus In South Africa you can “Go through” the vaccine to an extent From Pfizer / BioNTech Against COVID-19, a study in Israel found, although its presence in the country is low and the research has not been subject to peer review.
The study, released Saturday, compared nearly 400 people who had tested positive for COVID-19, 14 or more days after they received one or two doses of the vaccine, with the same number of patients who had the disease and had not been vaccinated. He matched age and gender, among other characteristics.
The South African alternative, B.1.351, accounts for 1% of all COVID-19 cases in the group of people studied, according to research from Tel Aviv University and Clalit, the largest healthcare provider in Israel.
But among patients who received two doses of the vaccine, the prevalence of the variant was eight times higher than that of the unvaccinated – 5.4% versus 0.7%.
The researchers said this indicates that the vaccine is less effective against the South African variant, compared to the original coronavirus and a variant initially identified in Britain that accounts for nearly all cases of COVID-19 in Israel.
We found a disproportionately higher rate for the South African variant among subjects vaccinated with a second dose, compared to the unvaccinated group. “This means that the South African alternative can, to some extent, go through vaccine protection,” said Eddy Stern of Tel Aviv University.
However, the researchers cautioned that the study included only a small sample of people with the South African variant, because it is so rare in Israel.
They also said that the research was not aimed at concluding the overall effectiveness of the vaccine against any variant, as it only took into account people who had already tested positive for COVID-19, not overall infection rates.
Pfizer and BioNTech could not be reached for comment outside of normal business hours.
On April 1, the companies said their vaccine was 91% effective in preventing COVID-19, citing updated test data that included participants who had been vaccinated for up to six months.
Copyright law strictly prohibits reproduction of all or part of Excelsior materials without first obtaining written permission and without including a link to the original text.